Latest News
Avingtrans subsidiary Adaptix secures FDA clearance for 3D orthopaedic imaging system
10 November 2025 - Avingtrans plc (AIM: AVG), a designer and manufacturer of critical systems for the energy, medical and industrial sectors, announced on Monday that its subsidiary Adaptix Limited has received 510(k) clearance from the U.S. Food and...
QIAGEN launches QIAsymphony Connect and showcases new precision oncology advances at AMP 2025
10 November 2025 - Netherlands-based holding company QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) announced on Monday that it unveiled QIAsymphony Connect, the next generation of its automated nucleic acid purification platform, at the As...
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL
10 November 2025 - Biotechnology company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) announced on Monday that it has received FDA clearance to proceed with its confirmatory Phase 3 TELLOMAK 3 trial evaluating lacutamab in patients with S&ea...
AN2 Therapeutics partners with GSK to develop boron-based TB therapies; Secures Gates Foundation funding
10 November 2025 - Biopharmaceutical company AN2 Therapeutics Inc (Nasdaq: ANTX) revealed on Monday that it has entered into a research collaboration with biopharmaceutical firm GSK to advance boron-based leucyl-tRNA synthetase (LeuRS) inhibitors tar...
Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests
10 November 2025 - Cancer screening and diagnostic tests provider Exact Sciences Corp (NASDAQ: EXAS) on Monday announced the expiration of the Hart-Scott-Rodino Antitrust Act waiting period for its previously disclosed license agreement with Freenome...